Last reviewed: June 29, 2026
Last updated: June 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has become one of the most requested weight loss medications, but it is not appropriate for everyone. The FDA approved semaglutide for chronic weight management in adults with a BMI of 30 or higher, or those with a BMI of 27 or higher plus at least one weight-related health condition. Before starting any GLP-1 therapy, your medical history must be carefully reviewed.
Who Qualifies for Semaglutide Weight Loss Treatment
The primary eligibility criteria for semaglutide therapy center on body mass index and metabolic health status. Adults with a BMI of 30 or greater typically qualify regardless of other conditions. Those with a BMI between 27 and 29.9 qualify if they have at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. PlexusDx evaluates each patient's individual health profile to determine if compounded semaglutide is a safe and appropriate option.
Age matters in the eligibility conversation. Semaglutide is approved for adults 18 and older, though clinical data in younger adults remains limited. Teenagers with severe obesity may be candidates, but this decision requires careful pediatric assessment. PlexusDx works with patients to ensure they meet both the clinical and safety requirements before starting treatment.
Medical Conditions That Affect Semaglutide Eligibility
Certain medical conditions make semaglutide inappropriate or require special monitoring. A personal or family history of medullary thyroid carcinoma is an absolute contraindication, as is a diagnosis of Multiple Endocrine Neoplasia syndrome type 2. Patients with active pancreatitis, severe kidney disease, or uncontrolled diabetes may need alternative approaches or closer medical supervision. PlexusDx reviews your complete medical history before recommending any GLP-1 based treatment.
Pregnancy and breastfeeding exclude women from semaglutide use, as animal studies suggest potential fetal risks. Women of childbearing age must use effective contraception while on therapy. Gallbladder disease, previous gastric surgery, and severe dehydration warrant careful discussion with a medical provider. PlexusDx coordinates with your primary care physician to ensure all medical factors are considered.
Medication Interactions and Drug History Considerations
Semaglutide can interact with other medications, particularly those for diabetes management and blood pressure control. Patients already on insulin or sulfonylureas may experience lower blood sugar levels when starting GLP-1 therapy, requiring dose adjustments by their physician. Certain diabetes medications work synergistically with semaglutide, improving overall metabolic outcomes. PlexusDx screens for these interactions and coordinates dosing recommendations with your healthcare team.
A history of eating disorders, depression, or suicidal thoughts requires disclosure, as GLP-1 medications can affect appetite regulation and mood in complex ways. Some patients report decreased interest in food beyond the medication's intended effect, while others experience mild mood changes. Full transparency about psychiatric history allows PlexusDx medical providers to monitor your mental health throughout treatment and recommend appropriate support.
How PlexusDx Personalizes Semaglutide Therapy for You
PlexusDx compounded semaglutide starts at $149 per month with no flat per-compound pricing increases—your dose may need to go up, but your price won't. All medications come from licensed 503A compounding pharmacies and are available in all 50 states without insurance requirements. PlexusDx accepts HSA and FSA payments, making treatment accessible to more patients. Your initial evaluation includes a detailed health screening, BMI assessment, and review of weight-related conditions to confirm eligibility.
The Precision Peptide Genetic Test ($99 add-on after your first month) maps your peptide pathways across 14 different mechanisms to identify which compounds—semaglutide, tirzepatide, or both—align best with your genetic predispositions. Key variants like GLP1R rs6923761 and GIPR rs1800437 influence how your body responds to GLP-1 therapy. This personalization helps PlexusDx recommend the right medication at the right starting dose, improving your chances of sustained weight loss and better tolerability.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What if my BMI is below 30 but I struggle with weight?
You may still qualify if your BMI is 27 or higher and you have at least one weight-related condition like type 2 diabetes, high blood pressure, or sleep apnea. PlexusDx reviews all qualifying health factors during your initial assessment to determine eligibility for compounded semaglutide therapy.
Does semaglutide work the same way in everyone's body?
No—genetic variation affects how your body processes GLP-1 signals. The PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R and GIPR genes that influence your response to semaglutide, helping predict which dose range and compound type will work best for your metabolism.
Can I afford semaglutide if I don't have insurance?
Yes. PlexusDx compounded semaglutide starts at $149 per month with no membership fees or insurance required. HSA and FSA accounts are accepted, and your price remains flat regardless of dose adjustments, making it accessible for uninsured and underinsured patients.
What happens if I have a history of thyroid cancer?
If you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, semaglutide is not safe for you. PlexusDx will discuss alternative weight loss approaches, including other compounded peptides or lifestyle-based strategies tailored to your medical profile.
How do I know if semaglutide or tirzepatide is right for me?
PlexusDx offers the Precision Peptide Genetic Test to map 14 peptide pathways and 150+ genetic insights. This test identifies which GLP-1 or dual-action compounds align with your body's genetic predispositions, increasing your likelihood of success on treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where Can I Get Ozempic Shots for Weight Loss: A Comprehensive Guide
Navigating Medications: Can You Take Prednisone with Wegovy for Weight Management?